Category
Chair, Speaker
IATDMCT
International Association of Therapeutic Drug Monitoring
and Clinical Toxicology
To get the latest update, please clear or refresh your web browser's cache.
*i.e. Google Chrome: Ctr + F5 keys
Lecture language E = English J = Japanese
( = Simultaneous Interpretation service is available.)
EL-1 | 9:40 - 10:30 | Sponsored by Waters CorporationE | ![]() |
Topic1:Expanding the Role of LC-MS/MS in Therapeutic Drug Monitoring (TDM)
Topic2:TDM by LC/MS-Single analyte, multiplexing and novel drugs
Chair: Jose Castro-Perez, USA
EL-2 | 10:40 - 11:30 | Sponsored by Shimadzu CorporationE | ![]() |
Modern targeted and untargeted LC-MS/MS screenings, and automated sample preparation system
1. Clinical Laboratory Innovation by LC-MS/MS
2. Modern targeted and untargeted LC-MS/MS screenings using low resolution systems
Chair: Akira Ishii, Japan
EL-3 | 13:30 - 13:55 | Sponsored by Abbott LaboratoriesE | ![]() |
State of the Art Immunosuppressant Methodologies and Clinical Considerations
Chair: Moe Kawai, Japan
EL-4 | 14:05 - 14:30 | Sponsored by Bruker Daltonics K.K.E | ![]() |
Chair: Markus Meyer, Germany
EL-5 | 14:40 - 15:05 | Sponsored by MSD K.K./Taiho Pharmaceutical Co., Ltd.E | ![]() ![]() |
Precision medicine in the lung cancer
Chair: Chiyo K. Imamura, Japan
EL-6 | 15:15 - 16:05 | Sponsored by ONO PHARMACEUTICAL CO., LTD. /Bristol-Myers Squibb K.K. |
E | ![]() |
Cancer immunotherapy - from basic research to clinic
Chair: Atsushi Otsuka, Japan
EL-7 | 16:15 - 17:05 | Sponsored by ONO PHARMACEUTICAL CO., LTD. /Bristol-Myers Squibb K.K. |
E | ![]() |
Chair: Atsushi Otsuka, Japan
EL-8 | 9:40 - 10:30 | Sponsored by Chugai Pharmaceutical Co., Ltd.E | ![]() |
Current status of Therapeutic Drug Monitoring of immunosuppressants
Chair: Satohiro Masuda, Japan
EL-9 | 10:40 - 11:30 | Sponsored by Novartis Pharma K.K.E | ![]() |
![]() |
Current Topics for Therapeutic Drug Monitoring of Immunosuppressive Drugs
~Pharmacokinetics, Pharmacogenetics, and TDM of Immunosuppressive Drugs~
Chair: Yoshihiko Watarai, Japan
EL-10 | 13:30 - 13:55 | Sponsored by Otsuka Pharmaceutical Co., Ltd.J | ![]() |
Reinforced molecular targeted therapy for Ph+ Leukemias based on risk-benefit assessment
リスク-ベネフィットを考慮したPh陽性白血病の第3世代分子標的治療
EL-11 | 14:05 - 14:30 | Sponsored by SHIONOGI & CO., LTD.J | ![]() |
Pharmacokinetics/Pharmacodynamics of Lusutrombopag, a Thrombopoietin Receptor Agonist, and Prediction of Platelet Count Profile
トロンボポエチン受容体アゴニスト・ルストロンボパグのPK/PDに基づく血小板数予測
Chair: Yoshitaka Yano, Japan
EL-12 | 14:40 - 15:05 | Sponsored by Eli Lilly Japan K.K.E | ![]() |
![]() |
The possibility of exposure response in ramucirumab therapy
Chair: Yuichi Ando, Japan
EL-13 | 15:15 - 16:05 | Sponsored by Chugai Pharmaceutical Co., Ltd.E | ![]() |
Exposure-response of erlotinib in patients with non-small cell lung cancer
Chair: Yasutsuna Sasaki, Japan
EL-14 | 16:15 - 17:05 | Sponsored by Shimadzu CorporationE | ![]() |
The Leading Edge of Therapeutic Monoclonal Antibody Monitoring:Paradigm Shift in Protein Bioanalysis by Mass Spectrometry
1.Novel monoclonal antibody bioanalysis from SHIMADZU: nano-surface and molecular-orientation limited (nSMOL) proteolysis
2.Therapeutic drug monitoring for monoclonal antibodies
Chair: Satohiro Masuda, Japan
EL-15 | 10:30 - 11:20 | Sponsored by Astellas Pharma IncE | ![]() |
Educational Lecture : A to Z of Tacrolimus
Chair: Kenji Yuzawa, Japan
EL-16 | 11:30 - 12:00 | E |
Drug of abuse crisis - interactions with therapeutics-role of clinical toxicologist
Chair: Marilyn A. Huestis, USA
EL-17 | 13:30 - 14:20 | Sponsored by Meiji Seika Pharma Co., Ltd.J | ![]() |
![]() |
PK/PD modeling and simulation approach to guide effective dosing strategy for antibiotic
モデル&シミュレーションを用いた抗菌薬のPK/PDと投与設計
Chair: Masato Homma, Japan
EL-18 | 14:40 - 15:05 | Sponsored by Roche Diagnostics International LtdE | ![]() |
Automated Drug Monitoring exploring new accuracy frontiers
1.TDM-Immunoassay goes LC-MS/MS
2.Drugs of abuse-Automated immunoassays for forensic drug testing?
Chair: Satohiro Masuda, Japan